Literature DB >> 8761945

Selenium-regulated translation control of heterologous gene expression: normal function of selenocysteine-substituted gene products.

J L Leonard1, D M Leonard, Q Shen, A P Farwell, P E Newburger.   

Abstract

In eukaryotes, the synthesis of selenoproteins depends on an exogenous supply of selenium, required for synthesis of the novel amino acid, selenocysteine, and on the presence of a "selenium translation element" in the 3' untranslated region of mRNA. The selenium translation element is required to re-interpret the stop codon, UGA, as coding for selenocysteine incorporation and chain elongation. Messenger RNA lacking the selenium translation element and/or an inadequate selenium supply lead to chain termination at the UGA codon. We exploited these properties to provide direct translational control of protein(s) encoded by transfected cDNAs. Selenium-dependent translation of mRNA transcribed from target cDNA was conferred by mutation of an in-frame UGU, coding for cysteine, to UGA, coding for either selenocysteine or termination, then fusing the mutated coding region to a 3' untranslated region containing the selenium translation element of the human cellular glutathione peroxidase gene. In this study, the biological consequences of placing this novel amino acid in the polypeptide chain was examined with two proteins of known function: the rat growth hormone receptor and human thyroid hormone receptor beta 1. UGA (opal) mutant-STE fusion constructs of the cDNAs encoding these two polypeptides showed selenium-dependent expression and their selenoprotein products maintained normal ligand binding and signal transduction. Thus, integration of selenocysteine had little or no consequence on the functional activity of the opal mutants; however, opal mutants were expressed at lower levels than their wild-type counterparts in transient expression assays. The ability to integrate this novel amino acid at predetermined positions in a polypeptide chain provides selenium-dependent translational control to the expression of a wide variety of target genes, allows facile 75Se radioisotopic labeling of the heterologous proteins, and permits site-specific heavy atom substitution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761945     DOI: 10.1002/(sici)1097-4644(19960601)61:3<410::aid-jcb8>3.0.co;2-w

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

Review 1.  Redox Regulation via Glutaredoxin-1 and Protein S-Glutathionylation.

Authors:  Reiko Matsui; Beatriz Ferran; Albin Oh; Dominique Croteau; Di Shao; Jingyan Han; David Richard Pimentel; Markus Michael Bachschmid
Journal:  Antioxid Redox Signal       Date:  2020-01-23       Impact factor: 8.401

Review 2.  Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities.

Authors:  Edith Lubos; Joseph Loscalzo; Diane E Handy
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

3.  Aminoglycosides decrease glutathione peroxidase-1 activity by interfering with selenocysteine incorporation.

Authors:  Diane E Handy; Gaozhen Hang; John Scolaro; Nicole Metes; Nadia Razaq; Yi Yang; Joseph Loscalzo
Journal:  J Biol Chem       Date:  2005-12-14       Impact factor: 5.157

4.  An RNA-binding protein recognizes a mammalian selenocysteine insertion sequence element required for cotranslational incorporation of selenocysteine.

Authors:  A Lesoon; A Mehta; R Singh; G M Chisolm; D M Driscoll
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

5.  Secondary-ion mass spectrometry of genetically encoded targets.

Authors:  Ingrid C Vreja; Selda Kabatas; Sinem K Saka; Katharina Kröhnert; Carmen Höschen; Felipe Opazo; Ulf Diederichsen; Silvio O Rizzoli
Journal:  Angew Chem Int Ed Engl       Date:  2015-03-17       Impact factor: 15.336

6.  Improving redox sensitivity of roGFP1 by incorporation of selenocysteine at position 147.

Authors:  Katherine R Stanford; Joanne M Ajmo; Parmvir K Bahia; Stephen H Hadley; Thomas E Taylor-Clark
Journal:  BMC Res Notes       Date:  2018-11-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.